What is Salignostics?
Salignostics is a leader in saliva-based diagnostics, offering accessible, rapid, and reliable testing solutions for healthcare providers, home-testing markets, and laboratories. The company's innovative platform overcomes the limitations of traditional diagnostic methods by providing non-invasive, cost-effective, and user-friendly testing options. A key technological advancement is their unique saliva concentrator technology, which improves biomarker detection and ensures consistent sample volume for accurate results. Salignostics is notably recognized for Salistick, the first CE-approved saliva-based pregnancy test, marking a significant achievement in the diagnostics industry.
How much funding has Salignostics raised?
Salignostics has raised a total of $8M across 1 funding round:
Series A
$8M
Series A (2022): $8M with participation from Avigdor Orlinsky
What's next for Salignostics?
The recent major strategic investment positions Salignostics for substantial growth and market expansion. This capital infusion is expected to accelerate the development and commercialization of their advanced saliva-based diagnostic technologies, potentially broadening their product portfolio and increasing their global reach. The company's focus on non-invasive testing solutions aligns with a growing trend in healthcare, suggesting a strong trajectory for future scaling and further rounds of financing as they solidify their market presence.
See full Salignostics company page
